Clinical outcomes of older and younger patients treated with loncastuximab tesirine in the LOTIS-2 clinical trial

Authors

Mehdi Hamadani, Medical College of Wisconsin
Brad Kahl, Washington University School of Medicine in St. Louis
et al.

Journal

Blood Advances

Publication Date

1-9-2024

Volume

8

Issue

1

First Page

93

Last Page

98

Document Type

Open Access Publication

DOI

10.1182/bloodadvances.2023010636

Rights and Permissions

Hamadani M, Spira A, Zhou X, Liao L, Chen L, Radford J, Ai W, Solh M, Ardeshna KM, Hess B, Caimi PF, Stathis A, Carlo-Stella C, Alderuccio JP, Kahl B, Wang Y, Qin Y, Xu ZC, Zinzani PL. Clinical outcomes of older and younger patients treated with loncastuximab tesirine in the LOTIS-2 clinical trial. Blood Adv. 2024 Jan 9;8(1):93-98. doi: 10.1182/bloodadvances.2023010636. © 2024 by The American Society of Hematology. Licensed under Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0), permitting only noncommercial, nonderivative use with attribution. All other rights reserved.

Recommended Citation

Hamadani, Mehdi; Kahl, Brad; and et al., "Clinical outcomes of older and younger patients treated with loncastuximab tesirine in the LOTIS-2 clinical trial." Blood Advances. 8, 1. 93 - 98. (2024).
https://digitalcommons.wustl.edu/oa_4/3484

Additional Links

Supplemental material is available for this article at publisher site.